K. Kolbe

发表

Current results on the use of imatinib mesylate in patients with relapsed Philadelphia chromosome positive leukemia after allogeneic or syngeneic hematopoietic stem cell transplantation.

H. Gschaidmeier, C. Huber, T. Fischer, 2003, The Keio journal of medicine.

Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B‐cell lymphoma: mature results of a phase II multicentre study

N. Schmitz, M. Gramatzki, H. Wolf, 2015, British journal of haematology.

Infectious complications during neutropenia subsequent to peripheral blood stem cell transplantation

C. Huber, S. Bhakdi, W. Aulitzky, 1997, Bone Marrow Transplantation.

Safety and feasibility of CHOP/rituximab induction treatment followed by high-dose chemo/radiotherapy and autologous PBSC-transplantation in patients with previously untreated mantle cell or indolent B-cell-non-Hodgkin's lymphoma

C. Huber, T. Fischer, G. Hess, 2003, Bone Marrow Transplantation.

Analysis of the p53 and MDM‐2 gene in acute myeloid leukemia

D. Huhn, B. Seliger, C. Huber, 1996, European journal of haematology.

Plasma levels of IL-1, TNF alpha, IL-6, IL-8, G-CSF, and IL1-RA during febrile neutropenia: Results of a prospective study in patients undergoing chemotherapy for acute myelogenous leukemia

M. Schuler, C. Peschel, C. Huber, 1995, Annals of Hematology.

High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

N. Schmitz, D. Niederwieser, K. Indrák, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of rituximab on the long-term outcome after high-dose therapy for relapsed B-cell non-Hodgkin’s lymphoma

M. Schuler, C. Huber, G. Hess, 2006, Annals of Hematology.

Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy in B-NHL

C. Huber, G. Hess, T. Flohr, 2002, Bone Marrow Transplantation.

First-line high-dose chemotherapy for patients with poor prognosis extragonadal germ cell tumors: the experience of the European Bone Marrow Transplantation (EBMT) Solid Tumors Working Party

S. Leyvraz, H. Wandt, U. Giorgi, 2004, Bone Marrow Transplantation.

Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia: results from the multicenter German cooperative study group

M. Labopin, C. Huber, A. Yaman, 2005, Bone Marrow Transplantation.

Effect of combination therapy with all-trans-retinoic acid and recombinant human granulocyte colony-stimulating factor in patients with myelodysplastic syndromes.

A. Ganser, B. Wörmann, O. Ottmann, 1994, Leukemia.

GM-CSF in a double-blind randomized, placebo controlled trial in therapy of adult patients with de novo acute myeloid leukemia (AML).

R. Mertelsmann, C. Huber, A. Lindemann, 1995, Leukemia.

Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.

H. Einsele, M. Egger, C. Schmoor, 2009, The Lancet. Oncology.

Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia

A. Ganser, W. Hofmann, L. Bergmann, 2004, Annals of Hematology.

Second German consensus on immunogenetic donor search for allotransplantation of hematopoietic stem cells

N. Schmitz, W. Siegert, H. Einsele, 2001, Annals of Hematology.

Posaconazole concentrations in the central nervous system.

M. Hallek, G. Fätkenheuer, F. Ebinger, 2008, The Journal of antimicrobial chemotherapy.

Acute kidney injury in a mouse model of meningococcal disease

I. L. Noronha, Margoth R. Garnica, Stephen R Thomas, 2021, International journal of immunopathology and pharmacology.

Reduced-intensity conditioning followed by allografting of CD34-selected stem cells and ≤106/kg T cells may have an adverse effect on transplant-related mortality

S. Kreiter, C. Huber, P. Schneider, 2005, Annals of Hematology.

174 Intensive chemotherapy (idarubicin, ARA-C, VP-16) combined with G-CSF-priming yields high remission rates in patients with advanced MDS and high-risk AML

A. Ganser, F. Herrmann, W. Hofmann, 1997 .

Filgrastim mobilization and collection of allogeneic blood progenitor cells from adult family donors: first interim report of a prospective German multicenter study

C. Scheid, W. Knauf, H. Sayer, 2002, Annals of Hematology.

Interleukin-2 bolus infusion as late consolidation therapy in 2nd remission of acute myeloblastic leukemia.

L. Bergmann, G. Heil, D. Hoelzer, 1995, Leukemia & lymphoma.

Aggressive chemotherapy combined with G-CSF and maintenance therapy with interleukin-2 for patients with advanced myelodysplastic syndrome, subacute or secondary acute myeloid leukemia — initial results

H. Heimpel, A. Ganser, L. Bergmann, 1993, Annals of Hematology.

Therapy of Advanced MDS, AML Evolving from MDS, or Secondary AML with Idarubicin Ara-C, VP-16, Followed by G-CSF-Priming Exhibits High Remission Rate

A. Ganser, F. Herrmann, W. Hofmann, 1998 .

Induction Therapy with Idarubicin, Ara-C, and VP-16, Followed by G-CSF and Maintenance Immunotherapy with Interleukin-2 for High-Risk AML

A. Ganser, W. Brockhaus, L. Bergmann, 1996 .

Effect of interleukin‐3 pretreatment on granulocyte/macrophage colony‐stimulating factor induced mobilization of circulating haemopoietic progenitor cells

D. Niederwieser, C. Peschel, A. Fritz, 1995, British journal of haematology.

depleted reduced-intensity transplantation - Prophylactic transfer of CD8-depleted donor lymphocytes after T-cell

C. Huber, G. Hess, C. Britten, 2013 .

Prophylactic transfer of CD8-depleted donor lymphocytes after T-cell-depleted reduced-intensity transplantation.

C. Huber, G. Hess, C. Britten, 2007, Blood.

Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML)

A. Ganser, W. Hofmann, W. Brockhaus, 2000, Annals of Hematology.

Clinical and prognostic significance of the Philadelphia chromosome in adult patients with acute lymphoblastic leukemia

D. Hossfeld, G. Dölken, D. Hoelzer, 1992, Annals of Hematology.

Improved outcome in adult B-cell acute lymphoblastic leukemia.

E. Thiel, W. Hiddemann, K. Uberla, 1996, Blood.

Effect of granulocyte-macrophage colony-stimulating factor on neutropenia and related morbidity induced by myelotoxic chemotherapy.

F. Herrmann, R. Mertelsmann, A. Lindemann, 1990, The American journal of medicine.

Salvage Therapy of Adult ALL

N. Schmitz, E. Thiel, W. Hiddemann, 1996 .

Nonmyeloablative stem cell transplantation in adults with high-risk ALL may be effective in early but not in advanced disease

A. Ho, U. Hegenbart, G. Ehninger, 2002, Leukemia.

Low-Dose Aclacinomycin and Intermediate-Dose Cytosine Arabinoside in Relapsed and Refractory Acute Myelogenous Leukemia

F. Herrmann, R. Mertelsmann, A. Lindemann, 1990 .

Transmission of angioimmunoblastic T-cell lymphoma by bone marrow transplant

A. Rosenwald, C. Kirkpatrick, A. Kreft, 2015, Leukemia & lymphoma.

Donor CD4 T cells convert mixed to full donor T-cell chimerism and replenish the CD52-positive T-cell pool after alemtuzumab-based T-cell-depleted allo-transplantation

C. Huber, R. Meyer, E. Roosnek, 2010, Bone Marrow Transplantation.

Potentiation of granulocyte colony-stimulating factor-induced mobilization of circulating progenitor cells by seven-day pretreatment with interleukin-3.

D. Niederwieser, C. Peschel, C. Huber, 1996, Blood.

Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius.

H. Einsele, M. Egger, C. Schmoor, 2011, Blood.

Granulocyte–Macrophage Colony-Stimulating Factor in the Therapy of Adults with De Novo Acute Myeloblastic Leukemia: An Update of a Double-Blind Randomized, Placebo-Controlled Trial

H. Heimpel, W. Gaus, R. Mertelsmann, 1997 .

Busulfan systemic exposure after oral administration of extemporeanously prepared high-dose busulfan capsules

I. Krämer, K. Kolbe, A. Karstens, 2010, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial.

H. Einsele, C. Schmoor, A. Zander, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Engraftment of T‐cell‐depleted allogeneic haematopoietic stem cells using a reduced intensity conditioning regimen

C. Craddock, J. Goldman, S. Kreiter, 2000, British journal of haematology.

Improved multilineage response of hematopoiesis in patients with myelodysplastic syndromes to a combination therapy with all-trans-retinoic acid, granulocyte colony-stimulating factor, erythropoietin and α-tocopherol

A. Ganser, O. Ottmann, D. Hoelzer, 1996, Annals of Hematology.

IL-2, IL-3, and IFN-gamma differently affect in vivo frequencies of circulating precursors of cytotoxic T lymphocytes (CTL-p)

G. Gerken, C. Peschel, C. Huber, 1993, Annals of Hematology.

Recovery of varicella-zoster virus-specific T cell immunity after T cell-depleted allogeneic transplantation requires symptomatic virus reactivation.

C. Huber, B. Plachter, R. Meyer, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Quantification of fluorescent STR genotyping results for chimerism control after bone marrow transplantation

S. Kreiter, P. Schneider, B. Stradmann-Bellinghausen, 2003 .

Do we Need a Triple Antibiotic Therapy

A. Ullmann, G. Heussel, K. Kolbe, 2001 .

Failure of sustained engraftment after non-myeloablative conditioning with low-dose TBI and T cell-reduced allogeneic peripheral stem cell transplantation

M. Schuler, S. Kreiter, C. Huber, 2001, Bone Marrow Transplantation.

Peripheral blood stem cell (PBSC) mobilization with chemotherapy followed by sequential IL-3 and G-CSF administration in extensively pretreated patients

C. Peschel, C. Huber, L. Färber, 1997, Bone Marrow Transplantation.

Improved Outcome for Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) with Poor Risk Cytogenetics – Result from An Analysis on 172 Patients Receiving FLAMSA-RIC Conditioning for Allogeneic Stem Cell Transplantatioin (SCT).

A. Ganser, E. Holler, H. Greinix, 2008 .

High dose mitoxantrone with thiotepa, cyclophosphamide and autologous stem cell rescue for high risk stage II and stage III breast cancer. German GABG-4/EH-93-Study.

N. Kröger, A. Zander, W. Jonat, 1996, Bone marrow transplantation.

Prior Treatment with Alemtuzumab Interferes with T-Cell Engraftment After Allogeneic Stem Cell Transplantation in Patients with Chronic Lymphocytic Leukemia.

W. Siegert, A. Kiani, G. Ehninger, 2009 .

Effect of granulocyte-macrophage colony-stimulating factor on neutropenia and related morbidity induced by myelotoxic chemotherapy.

F. Herrmann, R. Mertelsmann, A. Lindemann, 1990, The American journal of medicine.

Pharmacokinetics of nicotinic acid – salicylic acid interaction

L. Benet, E. Weber, J. Vries, 1989, Clinical pharmacology and therapeutics.

Healthcare-associated infections on the intensive care unit in 21 Brazilian hospitals during the early months of the coronavirus disease 2019 (COVID-19) pandemic: An ecological study

A. Levin, S. Costa, T. Guimarães, 2022, Infection Control & Hospital Epidemiology.

Preemptive Transfer of GMP-Grade CD8-Depleted Donor Lymphocytes after T-Cell Depleted Reduced-Intensity Transplantation.

C. Huber, C. Britten, R. Meyer, 2005 .

Chemotherapy with Idarubicin, Ara-C,VP-16, Amsacrine, Followed by G-CSF and Maintenance Immunotherapy with Interleukin-2 for Patients with High-Risk Acute Myeloid leukemia: a 3-Years Follow-Up

A. Ganser, W. Hofmann, W. Brockhaus, 1998 .

Comparison of killing activity of caspofungin against Candida parapsilosis , Candida orthopsilosis and Candida metapsilosis

M. Hallek, G. Fätkenheuer, F. Ebinger, 2008 .

Autologous Hematopoietic Stem Cell Transplantation (autoHSCT) in CLL: First Results of An EBMT Randomized Trial Comparing Autotransplant Versus Wait and Watch.

R. Brand, M. Hallek, A. Gratwohl, 2009 .

Concomitant granulocyte colony-stimulating factor and induction chemoradiotherapy in adult acute lymphoblastic leukemia: a randomized phase III trial.

T. Lipp, A. Ganser, M. Kneba, 1995, Blood.